GlassScriptPhysician profile
Amy B Freeman
NPI 1174062947
$4,689.56
in general payments reported to CMS, 2019-2025
31 companies · $1,140 in 2025
The $1,140 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $811 · 2022: $752 · 2023: $986 · 2024: $1,001 · 2025: $1,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,123.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $512.93 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $460.52 | 2021-2025 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $368.71 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $336.54 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $301.77 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $293.29 | 2021-2025 | |
| Lundbeck LLC | $147.89 | 2023-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $135.50 | 2022-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $121.06 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $118.09 | 2022 | |
| Exact Sciences Corporation | $79.19 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $75.07 | 2021-2022 | |
| Axsome Therapeutics, INC. | $64.70 | 2025 | Auvelity |
| Mylan Specialty L.P. | $53.48 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $53.10 | 2021-2024 | |
| Biogen, INC. | $50.93 | 2025 | Skyclarys |
| Janssen Pharmaceuticals, INC | $44.47 | 2021-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $43.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.77 | 2022 | |
| Shield Therapeutics INC | $37.54 | 2023 | Accrufer |
| Dexcom, INC. | $35.79 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.07 | 2025 | Caplyta |
| Baxter Healthcare | $28.27 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Corium, LLC | $20.68 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $20.40 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $20.17 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.15 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.18 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $15.03 | 2023 | Quviviq |
| Amarin Pharma, INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.